Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Ceska

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Neuro Endocrinology Letters|November 22, 2011
APOE polymorphism as a potential determinant of functional fitness in the elderly regardless of nutritional statusMichaela Snejdrlova, Zdenek Kalvach, Eva Topinkova, et al.
American Heart Journal|July 10, 2003
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteineVojtech Melenovsky, Tomas Stulc, Viktor Kozich, et al.
Plos One|November 16, 2012
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapyMary P McGowan, Jean-Claude Tardif, Richard Ceska, et al.
Clinical Chemistry and Laboratory Medicine|July 8, 2008
APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levelsJaroslav A Hubacek, Wu-Wei Wang, Zdena Skodová, et al.
Diabetes Care|March 3, 2022
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin TherapyHenry N Ginsberg, Neil J Hounslow, Yusuke Senko, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
Current Atherosclerosis Reports|June 24, 2019
The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH ProjectRichard Ceska, Gustavs Latkovskis, Marat V Ezhov, et al.
Frontiers in Cardiovascular Medicine|July 5, 2023
Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE studyMaciej Banach, Joanna Lewek, Kaja Pol, et al.
The New England Journal of Medicine|April 1, 2014
A 52-week placebo-controlled trial of evolocumab in hyperlipidemiaDirk J Blom, Tomas Hala, Michael Bolognese, et al.
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Neuro Endocrinology Letters|November 22, 2011
APOE polymorphism as a potential determinant of functional fitness in the elderly regardless of nutritional statusMichaela Snejdrlova, Zdenek Kalvach, Eva Topinkova, et al.
American Heart Journal|July 10, 2003
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteineVojtech Melenovsky, Tomas Stulc, Viktor Kozich, et al.
Plos One|November 16, 2012
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapyMary P McGowan, Jean-Claude Tardif, Richard Ceska, et al.
Clinical Chemistry and Laboratory Medicine|July 8, 2008
APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levelsJaroslav A Hubacek, Wu-Wei Wang, Zdena Skodová, et al.
Diabetes Care|March 3, 2022
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin TherapyHenry N Ginsberg, Neil J Hounslow, Yusuke Senko, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
Current Atherosclerosis Reports|June 24, 2019
The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH ProjectRichard Ceska, Gustavs Latkovskis, Marat V Ezhov, et al.
Frontiers in Cardiovascular Medicine|July 5, 2023
Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE studyMaciej Banach, Joanna Lewek, Kaja Pol, et al.
The New England Journal of Medicine|April 1, 2014
A 52-week placebo-controlled trial of evolocumab in hyperlipidemiaDirk J Blom, Tomas Hala, Michael Bolognese, et al.
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Pageof 6